Clinical DevelopmentVivani Medical is preparing to start its clinical development for NPM-139 for chronic weight management, with the potential to demonstrate efficacy comparable to Wegovy.
Financial PerformanceThe company's cash position was significantly strengthened by a direct offering and private placement, raising $15.7M.
Market InterestThe market's interest in obesity-related assets, as demonstrated by Pfizer's acquisition, indicates a promising outlook for Vivani.